QUOTE AND NEWS
Benzinga  Aug 6  Comment 
BioCryst Pharmaceuticals, Inc., (NASDAQ: BCRX) today announced that Robert A. Ingram was elected to the Company's Board of Directors. "The Board of Directors and Leadership Team of BioCryst are very pleased to have Bob Ingram join the Company's...
Benzinga  Jul 18  Comment 
Let’s take a look at Friday’s after-hours movers; investors should monitor these names next Monday. The biggest gainer on Friday afternoon was Tallgrass Energy GP LP (NYSE: TEGP), which traded up more than 4.4 percent, at $31.21,...
Benzinga  Jul 2  Comment 
https://www.fbo.gov/index?s=opportunity&mode=form&id=fe6ad472c84d2b3c6df... © 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga  Jun 30  Comment 
Bank of America upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) from Neutral to Buy. The price target for BioCryst Pharmaceuticals has been raised from $12.00 to $19.00. BioCryst Pharmaceuticals shares have gained 10.75 percent over...
Benzinga  Jun 30  Comment 
In a report published Tuesday, BofA Merrill Lynch analyst Tazeen Ahmad upgraded the rating on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) from Neutral to Buy, while raising the price target from $12 to $19. Analyst Tazeen Ahmad commented that...
Capital Essence's Investment Blog- 錢途集團 » Page not found  Jun 19  Comment 
Wednesday’s bullish breakout had helped putting the bulls into the driver side of the market. However, given the looming resistance near S&P’s 2134, there is no big commitment to accumulate stocks aggressively at this point. What this means...
Benzinga  May 13  Comment 
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. Discovered by BioCryst,...
Benzinga  May 11  Comment 
In a report published Monday, Oppenheimer analysts maintained a Perform rating on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), saying that clinical data could drive the stock higher in 2H15. BioCryst reported its 1Q15 revenue and EPS at...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki